ARTL vs EXPE · $15.6M cap vs P/E 20, rev $7.74B
Artelo Biosciences Inc (ARTL) versus Expedia Group Inc. (EXPE) — a side-by-side from cached financials, not a winner call.
Artelo Biosciences Inc (ARTL) is a biotechnology company listed on US.
Expedia Group Inc. (EXPE) is a travel services company listed on US.
ARTL does not have a complete income-statement cache yet.
Latest reported EXPE revenue for 2026-06-30 was $7.74B. Net income was $872.0M. EXPE currently screens at market cap $21.71B and trailing P/E 20.4.
ARTL currently screens at market cap $15.6M. EXPE currently screens at market cap $21.71B and trailing P/E 20.4.
Not investment advice. Open the ARTL and EXPE stock pages for the full models.
Not investment advice.